Alto management will participate in several investor conferences this September, including HCW, Baird’s 2026 Global Healthcare Conference & TD Cowen’s Neuropsychiatry Summit. Webcasts will be available on our website following each session. Read more: businesswire.com/news/home/2…

We’re excited to collaborate with @Brainclinics on the TDBRAIN Prediction Challenge, inviting researchers, students & AI/ML specialists to develop and validate EEG-based biomarkers for major depressive disorder and treatment response. Learn more: brainclinics.com/research/br…

We’re pleased to announce the promotion of Nick Smith to President and Chief Financial Officer of @AltoNeuro. In his expanded role, Nick will continue to lead finance while overseeing corporate strategy and business development. investors.altoneuroscience.c… #PrecisionPsychiatry

Yesterday, @AltoNeuro reported second quarter 2026 financial results and recent business highlights. Learn more here: businesswire.com/news/home/2… #neuroscience #precision #psychiatry

Our CEO, Dr. Etkin, spoke with @BioTuesdays about @AltoNeuro’s precision psychiatry approach and how biomarkers can help move mental health treatment beyond trial and error. Read more here: biotuesdays.com/2026/08/04/a… #Neuroscience

Our CEO, Dr. Etkin, joined @GrinsteinJ, PhD, on Behind the Breakthroughs, a podcast from @Inside_PM, to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health. insideprecisionmedicine.com/… #Neuroscience

With today’s financing, @AltoNeuro is positioned to advance ALTO-207 into its next stage of development. The company plans to accelerate its clinical program, including an additional Ph3 trial evaluating ALTO-207. Learn more here: investors.altoneuroscience.c… #PrecisionPsychiatry

@AltoNeuro is excited to participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (Hybrid). Hear from our leadership team on our mission to redefine psychiatry with personalized precision medicines. Learn more here: hcwevents.com/neuro-perspect… #Biotech

Ph2 findings for ALTO-203 showed improvements in attention, alertness, & EEG biomarkers in patients with depression. In a recent @PsychTimes interview, Amit Etkin, MD, PhD, discusses how these findings may help identify patients most likely to benefit. bit.ly/444zSdI

We’re excited to announce the appointment of Andrew Miller, Ph.D., to @AltoNeuro Board of Directors, effective May 27, 2026. Andrew brings extensive leadership experience across neuroscience, biotechnology, & precision medicine. businesswire.com/news/home/2…

@AltoNeuro Founder & CEO Amit Etkin, M.D., Ph.D., has received the Transformational Research Award from Columbia University VP&S Alumni Association, recognizing his leadership in advancing precision psychiatry and biomarker-based innovation. Full video: bit.ly/3PiM86P

Today, @AltoNeuro reported first quarter 2026 financial results and recent business highlights. Learn more here: investors.altoneuroscience.c…

@AltoNeuro is heading to @BofA_News Healthcare Conference and @Jefferies Global Healthcare Conference. Hear from our leadership team as we advance our robust clinical-stage pipeline across mental health conditions. Learn more: businesswire.com/news/home/2… #PrecisionPsychiatry

At #SOBP2026, @AltoNeuro presented Phase 2a data for ALTO-207 in MDD. Statistically significant antidepressant effects and favorable tolerability support ongoing Phase 2b development in TRD. Read more here: businesswire.com/news/home/2… #Neuroscience #Neuroscience

@AltoNeuro launches Phase 2b trial of ALTO-207 in treatment-resistant depression. · Built on strong PAX-D efficacy signal · Designed for improved tolerability · Registrationally aligned study Data expected 2H 2027.  Read more: investors.altoneuroscience.c…

Our CEO, Dr. @AmitEtkin, joined The BioHub Podcast to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health. Listen on Spotify, Apple Podcasts, or LinkedIn. linkedin.com/posts/max-brenn… #Neuroscience #MentalHealth #HealthcareInnovation

Today, @AltoNeuro reported full-year 2025 financial results and recent business highlights. Learn more about our pipeline and upcoming milestones here: investors.altoneuroscience.c…

@AltoNeuro is excited to present at the Stifel 2026 Virtual CNS Forum - hear from our leadership team on March 17th at 12pm ET about our mission to redefine psychiatry with precision medicine. Learn more here: investors.altoneuroscience.c… #PrecisionPsychiatry #StifelCNS

Alto Neuroscience is heading to TD Cowen and Jefferies Biotech on the Beach this month! Hear from our leadership team on our mission to redefine psychiatry with personalized precision medicines. Learn more: lnkd.in/gXcqBEpN #AltoNeuroscience #PrecisionPsychiatry

Our CEO, Dr. @AmitEtkin, joined @thehctheory to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health. Listen on #Spotify, #ApplePodcasts, or #thehctheory website. thehealthcaretheory.org/a-ne… #Neuroscience #MentalHealth #HealthcareInnovation